Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of ruxolitinib with brentuximab vedotin or nivolumab in relapsed/refractory classical Hodgkin lymphoma
2019-003084-21Phase 2Active
- Sponsor
- PROF.BRUNANGELO FALINI, DR.ENRICO TIACCI. DIPARTIMENTO DI MEDICINA, UNIVERSITA' DI PERUGIA
- Start
- Jun 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruxolitinib, brentuximab vedotin and nivolumab in classical Hodgkin lymphoma (cHL) (2 cohorts), sponsored by PROF.BRUNANGELO FALINI, DR.ENRICO TIACCI. DIPARTIMENTO DI MEDICINA, UNIVERSITA' DI PERUGIA. Primary endpoints: Complete response rate by end of treatment in Cohort 1, Complete response rate by end of treatment in Cohort 2 and 1 more. Started Jun 2021; status: active.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2019-003084-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003084-21.